

# Genome-Wide Identification of High-Affinity Estrogen Response Elements in Human and Mouse

VÉRONIQUE BOURDEAU, JULIE DESCHÊNES, RAPHAËL MÉTIVIER, YOSHIHIKO NAGAI, DENIS NGUYEN, NANCY BRETSCHEIDER, FRANK GANNON, JOHN H. WHITE, AND SYLVIE MADER

*Département de Biochimie (V.B., J.D., D.N., S.M.), Université de Montréal, Montréal, Québec, Canada H3C 3J7; Departments of Physiology (V.B., J.H.W.), and Medicine (J.H.W., S.M.), McGill University, Montréal, Québec, Canada H3G 1Y6; McGill University and Genome Québec Innovation Centre (Y.N.), Montréal, Québec, Canada H3A 1A4; and European Molecular Biology Laboratories (R.M., N.B., F.G.), D-69117 Heidelberg, Germany*

Although estrogen receptors (ERs) recognize 15-bp palindromic estrogen response elements (EREs) with maximal affinity *in vitro*, few near-consensus sequences have been characterized in estrogen target genes. Here we report the design of a genome-wide screen for high-affinity EREs and the identification of approximately 70,000 motifs in the human and mouse genomes. EREs are enriched in regions proximal to the transcriptional start sites, and approximately 1% of elements appear conserved in the flanking regions (–10 kb to +5 kb) of orthologous human and mouse genes. Conserved and nonconserved elements were also found, often in multiple occurrences, in more than 230 estrogen-stimulated human genes previously identified from expression studies. In genes con-

taining known EREs, we also identified additional distal elements, sometimes with higher *in vitro* binding affinity and/or better conservation between the species considered. Chromatin immunoprecipitation experiments in breast cancer cell lines indicate that most novel elements present in responsive genes bind ER $\alpha$  *in vivo*, including some EREs located up to approximately 10 kb from transcriptional start sites. Our results demonstrate that near-consensus EREs occur frequently in both genomes and that whereas chromatin structure likely modulates access to binding sites, far upstream elements can be evolutionarily conserved and bind ERs *in vivo*. (*Molecular Endocrinology* 18: 1411–1427, 2004)

**E**STROGENS, SUCH AS 17 $\beta$ -estradiol (E2), are steroid hormones produced mainly by the ovary and act by endocrine, paracrine, and possibly autocrine mechanisms on a number of target tissues. Their

Abbreviations: ADORA1, Adenosine A1 receptor; C3, complement component 3; CASP7, caspase7, apoptosis-related cysteine protease; CDS, coding sequence; ChIP, chromatin immunoprecipitation; COX7A2L, cytochrome c oxidase subunit VIIa polypeptide 2 like; CTSD, cathepsin D; E2, 17 $\beta$ -estradiol; EBAG9, estrogen receptor binding site associated, antigen 9; EFP, estrogen-responsive finger protein; ER, estrogen receptor; ERE, estrogen response element; FGF, fibroblast growth factor; GAD2, glutamate decarboxylase 2; GAPD, glyceraldehydes-3-phosphate dehydrogenase; GREB1, gene regulated by estrogen in breast cancer protein; IGFBP4, IGF binding protein 4; KHDRBS3 (T-STAR/ETOILE), KH domain containing, RNA binding, signal transduction associated 3; LY6E, lymphocyte antigen 6 complex, locus E; NRIP1 (RIP140), nuclear receptor interacting protein 1; OVGP1, oviductal glycoprotein 1; P-PolIII, phosphorylated RNA polymerase II; RBM, RNA-binding motif; RNF14, ring finger protein 14; SCN1A, sodium channel, nonvoltage-gated 1 $\alpha$ ; TBP, TATA box binding protein; TERT, telomerase reverse transcriptase; TESK1, testis-specific kinase 1; TFF1/pS2, trefoil factor 1; TSHB, TSH $\beta$ ; VitA2, *Xenopus* vitellogenin A2; ZNF147, zinc finger protein 147.

**Molecular Endocrinology** is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

actions on the reproductive, cardiovascular, and central nervous systems and on bone (1–4) are mediated by two estrogen receptors, ER $\alpha$  and ER $\beta$  (4, 5), members of the nuclear receptor superfamily of ligand-inducible transcription factors (6–9). A central DNA binding domain, which corresponds to the conserved C region (10, 11), is responsible for primary sequence recognition and cooperative binding by receptor dimers on elements containing two appropriately spaced copies of specific recognition motifs. The ligand binding domain contains a strong dimerization interface that stabilizes receptor homodimers or heterodimers (12–14) and enhances binding to imperfect motifs and even to single copies of recognition motifs (11, 15–17). However, ERs bind with highest affinity to 15-bp palindromes composed of PuGGTCA motifs separated by three variable bp (17–19). These estrogen response elements (EREs) are recognized by ERs with high specificity, because other nuclear receptors bind either different motifs or similar motifs with different spacing and/or orientation (7, 19–21). Studies using chromatin immunoprecipitation approaches have demonstrated that ER binding to EREs is hormone inducible *in vivo* (22–25) and results in the ordered recruitment of a series of coactivator complexes, leading to histone acetylation, chromatin

remodeling, and enhanced recruitment of the basal transcription machinery (26–33).


Surprisingly, only a few near-consensus EREs have been characterized to date in the promoters of E2-regulated human or mouse genes. This probably reflects, in part, the fact that ERs can mediate estrogenic regulation through multiple mechanisms, including tethering to DNA via protein-protein interactions with other transcription factors (19, 34, 35), or so-called “nongenomic” effects, which affect gene expression by modulating the activity of upstream components of various intracellular signaling pathways (36–38). The paucity of known near-consensus EREs may also result from the fact that their presence is usually investigated only in relatively proximal sequences of E2-responsive genes. However, with sequences of the human and mouse genomes now available, genome-wide screening strategies can be used to expand the repertoire of potential high-affinity ER-binding sites.

In this study, we have sought to identify high-affinity EREs in the human and mouse genomes and to determine whether these elements represent *bona fide* ER binding sites *in vivo*. Indeed, little is known about the effect of chromatin structure or promoter context on ER binding *in vivo*. In addition, it is not clear how far from transcription start sites EREs can be positioned to recruit ERs and play a role in regulating gene expression. Our characterization of high-affinity EREs in the human and mouse genomes will greatly facilitate the study of the mechanisms modulating accessibility of ERs to their binding sites and of the subsequent events leading to transcriptional regulation by estrogen. This analysis will also provide a powerful resource for researchers analyzing the molecular events underlying the broad-ranging physiological actions of estrogens.

## RESULTS

### Identification of Sequences Corresponding to High-Affinity ER Binding Sites *in Vitro*

Palindromic response elements composed of two PuGGTCA motifs separated by 3 bp, such as the one found in the *Xenopus* vitellogenin A2 (VitA2) promoter, represent the highest affinity binding sites for ERs *in vitro* (Fig. 1A) (17–19). Surprisingly, only three perfect palindromic EREs have been identified to date in the vicinity of E2-regulated genes in the human genome. These genes, EBAG9, COX7A2L, and EFP/ZNF147, were cloned by screening of a CpG island genomic library for binding to ERs (39–41). In addition, a few near-consensus EREs have been characterized in human E2-responsive genes (see Table 1 for EREs diverging from consensus at one or two positions). A systematic analysis of single nucleotide substitutions in gel shift assays indicates that all elements with one variation still bind ERs *in vitro* (Fig. 1B). However, some replacements were more detrimental than oth-



**Fig. 1.** *In vitro* Binding of ERs to Consensus and Near-Consensus EREs

A, Consensus ERE with base numbering used in this study. B, Binding of human ER $\alpha$  or ER $\beta$  to response elements derived from the vitellogenin A2 (VitA2) ERE carrying a single replacement in one of the two arms of the palindrome. C, Binding of human ER $\alpha$  or ER $\beta$  to response elements derived from the VitA2 ERE carrying two symmetrical replacements. The percentage of probe found in a specific complex with human ER $\alpha$  or ER $\beta$  was quantified by phosphor imager and is shown with the corresponding SEM values.

ers (–5C, –4C, –2A), reflecting steric or charge clashes between specific ER amino acids and bases of the variant EREs (Nguyen, D., G. Pesant, S. Cheinberg, and S. Mader, in preparation). Note that, as expected from the high degree of homology between the DNA binding domains of ER $\alpha$  and ER $\beta$  (90% in region C as defined in Ref. 10), all mutations had a similar impact on complex formation by the two receptors. Introduction of symmetrical replacements in both arms of the palindrome generally affected ER binding much more drastically than when a unilateral change was introduced, although a few replacements were well tolerated even when present in both arms (Fig. 1C). Interestingly, examination of the known natural elements containing two replacements indicates that they all contain one change with mild effect on affinity (–6Py/+6Pu or –1G/+1C; Fig. 1, B and C and Table 1) combined with another replacement.

### Screening the Human And Mouse Genomes for High-Affinity EREs

Based on the above-described observations, we decided to identify all occurrences of EREs conforming to consensus, or with one variation, or with two vari-

**Table 1.** EREs in the Human Genome and Corresponding Elements in the Mouse Genome

HUMAN GENOME					MOUSE GENOME				
Symbol	UniGene #	ERE sequence	Pos.	Ref	Symbol	UniGene #	ERE sequence	Pos.	Ref
<b>PREVIOUSLY CHARACTERIZED EREs</b>									
<b>Perfect elements</b>									
EFF <sup>b</sup>	Hs.1579	GGGTCAATGGTGACCC	+23,088	39	Trim25 <sup>b</sup>	Mm.248445	AGGgCAGGGTGACCT	+17,499	
EBAG9	Hs.9222	GGGTCAAGGTGACCT	+6 (-64)	40	Ebag9	Mm.287896	GGGTCAAGGTGACCT	-4886	
COX7A2L	Hs.423404	GGGTCAAGGTGACCC	+383 (+443)	40	Cox7A2l	Mm.30072	GGGTCAAGGTGACCC	+336	
<b>1 mismatch</b>									
OVGP1	Hs.1154	GGGTCACTGTGACTC	-156 (-170)	74	Ovgp1	Mm.5110	cGGTCATTTGTGACTc	-110 (-110)	75
AGT	Hs.19383	AGGgCATCGTGACCC	-10 (-25)	76	Agt	Mm.285467	AGGTCACCTTGACCC	-2379 (-2742)	77
<b>2 mismatches</b>									
pS2 / TFF1	Hs.350470	AGGTCACGGTGgCCa	-392 (-406)	78	Tff1	Mm.2854	ctGTCATCTTgTcCa	-462*	
OXT	Hs.113216	cGGTgACCTTGACCC	-166 (-168)	79	Oxt	Mm.16745	cGaTgACCTTGACCC	-210*	
BCL2	Hs.79241	tGGTCcACCTTGACCC	+319 (+276)	80	Bel2	Mm.233518	tGGTCcATCTTGACCC	+279	
F12	Hs.1321	AGGgCAGCTTGACCa	-30 (-47)	81	F12	Mm.42224	GaGcaAGCTTGACCa	-75*	
TERT	Hs.439911	tGGTCAGGCTGAtCT	-2687 (-2677)	82	Tert	Mm.10109			
C3	Hs.284394	AGGTgCCCTTGACCC	-226 (-237)	83	C3	Mm.19131	AtcTggCCTTGACCC	-208*	
CTSD	Hs.343475	GGGcCgGGCTTGACCC	-125 (-270)	84	Ctsd	Mm.231395			
LTF	Hs.437457	AGGTCAAGGcGAtCT	-81 (-358)	85	Ltf	Mm.282359	AGGTCAAGGTaACCC	-340 (-342)	86
<b>OTHER ELEMENTS FOUND IN ESTROGEN TARGET GENES WITH KNOWN EREs</b>									
C3	Hs.284394	GGGTcTTGTGACCg	-9210						
CTSD	Hs.343475	GGGcCACCATGACCC	-8763		Ctsd	Mm.231395	AGGcCAATCTGACCT	-8157	
TERT	Hs.439911	GGGcCAGAGTGACCC	-5663						
OXT	Hs.113216	AGGTCAGCTTGACCCg	-2465		Oxt	Mm.16745	tGGTCACCGTGAAtCC	-5424	
LTF	Hs.437457	AGGTgAGTCTGACCa	-1166						
OVGP1	Hs.1154	GGGTcCcCTTGACCT	+200		Ovgp1	Mm.5110	AGGTCAGGATGtCtg	+866*	
COX7A2L	Hs.423404	AGGTCAGGATGcCCa	-5246						
EFF <sup>b</sup>	Hs.1579	AGGgCAGGGTGACCT	+22,583		Trim25 <sup>b</sup>	Mm.248445	AGGgCAGGGTGACCT	+17,499	
<b>SELECTED NEW ELEMENTS (used for gel shift and/or ChIP experiments)</b>									
ADORA1	Hs.77867	AGGTtAGGGTGACCT	-1171	54					
		GGGTCAAGGTGAACT	-486						
		GGGTcGgGGTGAACT	-392						
		GGGTCAAGGTGAACT	-312						
CASP7	Hs.9216	GGGTCAAGGTGAACT	-272	87	Casp7	Mm.298737	GtGTCAACTTGACCa	+1458	
		GGGTCAAGGTGAAcG	-232						
		tGGTCAGGGTGAACT	-195						
		GGGTCAAGGTGAACT	-141						
GAPD	Hs.169476	AGGcATCGTGACCT	-738	88	Gapd	Mm.288146	AGGTCAGGATGcCCT	-745	
		AGGTCAAAATGACCT	-21,207						
GREB1	Hs.438037	AGGTCATCATGACCT	-9517	89	Greb1 <sup>c</sup>	Mm.218957	AGGTCgCGCTGACCC	-7666	
		GGGTCAATCTGACCT	-1583				AGGTCAGGATGACCC	-3289	
IGFBP4	Hs.1516	AGGTCATTGTGACaC	-4124	54	Igfbp4	Mm.233799	AgatCAAGCTGACCT	-6697	
LY6E	Hs.77667	GGGcCAAGATGACCT	-499	54					
NRIP1	Hs.155017	GGGTCACTTTGACCC	-706	54	Nrip1	Mm.20895	AGGTCATTTTGACCC	-636	
SCN1A	Hs.446415	AGGTCAGCCTcACCC	-559	54					
GAD2	Hs.231829	AGGTCgCAGTGACCT	-564		Gad2	Mm.4784	AGGTCACAGcGACCT	-349	
TSHB	Hs.406687	AGGTCAGCTTGACaT	-4099	59	Tshb	Mm.110730	AtGTCAAAGCTGACCT	-535	

The sequence of previously characterized consensus EREs or elements with one or two mismatches in the human genome are shown with the corresponding references. Positions of the EREs with respect to the 5'-ends of mRNAs are as indicated in genomic data files, and may differ slightly from the positions (*in brackets*) indicated in the references. All other EREs in this table (selected examples from Table 3) were identified through our genomic screens (except for a few elements in mouse orthologs, identified by *asterisks*, which due to a higher number of mismatches were identified manually). References provided for novel EREs describe estrogenic regulation of the corresponding gene.

<sup>a</sup> EFP is now called ZNF147 in the human genome database.

<sup>b</sup> Trim25, the EFP/ZNF147 mouse homolog, corresponds to LOC217069.

<sup>c</sup> Greb1, also referenced as Greb1-pending, corresponds to 5730583K22Rik.

ations including either -6Py/+6Pu or -1G/+1C. This defines 588 different sets of 15-bp sequences with random 3-bp spacers; 71,119 elements were identified in the human genome and 65,012 were identified in mouse. Note that the elements containing CpG dinucleotides were found to be largely underrepresented in both genomes (data not shown), consistent with the lower genomic frequency of this dinucleotide due to deamination of the methylated C (42). In particular, symmetrical palindromes containing PuG-GTcG motifs (two CpGs), which represent good ER-binding sites (Fig. 1C), were found only 14 times in the human genome, whereas consensus palindromes were represented 891 times. The distribution of consensus EREs among the chromosomes is generally consistent with chromosomal size in both genomes

(Fig. 2, A and B). Whereas perfect EREs were not clustered together, several imperfect palindromes were found to be part of tandem repeat elements at different chromosomal locations in the human and mouse genomes, increasing the frequency of these elements (Bourdeau, V., Y. Nagai, and S. Mader, in preparation).

The numbers of near-consensus EREs found in the human and mouse genomes suggest that functional EREs should be found in the vicinity of genes more frequently than reported to date. Note that most previously identified EREs are located within 0.5 kb of transcriptional start sites (see Previously Characterized EREs in Table 1, with the exception of the TERT and the EFP/ZNF147 EREs). It is not clear whether this bias reflects a functional requirement for proximal

EREs or the fact that searches for EREs in E2 target genes usually focus on promoter sequences immediately upstream of the transcriptional start site. Using a cut-off distance of  $-10$  to  $+5$  kb from transcriptional start sites, we found EREs in the vicinity of 17,353 transcriptional start sites in human, and 15,284 in mouse (see web site at URL: <http://mapageweb.umontreal.ca/maders/eredatabase/>) Note that the number of genes containing EREs is slightly smaller (12,515 in human and 11,810 in mouse), as there can be several mRNAs and more than one ERE per gene. We further examined the distribution of EREs in the  $-10$  to  $+5$ -kb region with respect to the 5'-end of mRNAs (whenever several mRNAs are mapped, distances were calculated to the most 5'-initiation site). Note that EREs found close to more than one gene were counted several times for characterization of the distribution with respect to transcriptional start sites. Surprisingly, EREs were more abundant in the 0 to  $+1$ -kb region around transcriptional start sites in both genomes (excess of  $\sim 25\%$ ), whereas the number of elements found upstream of  $-1$  kb or downstream of  $+2$  kb were usually near or below the average number of near-consensus EREs found per kb between  $-10$  and  $+5$  kb (Fig. 2C). Compared with the frequency expected from random distribution of all EREs found in the genome, the number of individual EREs in the  $-1$  to  $+2$ -kb region of 5'-mRNAs was higher than expected by 64% in human and 29% in mouse (data not shown).

These data suggest that the distribution of near-consensus EREs reflects mostly a random distribution of these sequences in the different chromosomes, with enrichment in the close vicinity of transcriptional start sites. The large total number of EREs located in the vicinity ( $-10$  to  $+5$  kb) of transcriptional start sites may suggest that these elements can mediate regulation of a much larger fraction of the genome in different estrogen target tissues than previously recognized. However, some of these elements may not represent binding sites *in vivo*, possibly because of chromatin accessibility, and/or may not participate in transcriptional regulation.


### Identification of EREs Conserved in Human and Mouse

Near-consensus EREs previously identified in human genes often have counterparts at similar positions in their mouse orthologs (Table 1). Because conservation of newly identified EREs between the two species may indicate a functional role of these elements, we searched for the presence of EREs located in known human and mouse orthologs with less than 2 kb difference in distance from their respective transcriptional start sites (see *Materials and Methods*). EREs in 660 different pairs of orthologs were thus identified (supplemental Table 1; published as supplemental data on The Endocrine Society's Journals Online web site at <http://mend.endojournals.org>). As expected

from the distribution of EREs in the vicinity of genes, conserved EREs were also more abundant in the 0 to  $+1$ -kb region after the transcription start site (Fig. 2C; note that this analysis was intentionally limited to the  $-8$  to  $+3$ -kb region. The numbers of conserved EREs found between  $-10$  and  $-8$  kb or  $+3$  and  $+5$  kb would appear artificially low, because a conserved ERE found at a distance of 2 kb or less in the other species may not be included in the  $-10$  to  $+5$ -kb window from the transcriptional start site). However, conserved EREs were proportionately more represented in the 0 to  $+2$ -kb region than bulk EREs, whereas elements in the  $-5$  to  $-8$ -kb region were markedly less represented (Fig. 2C). Nevertheless, we note that a significant number of conserved EREs mapped between  $-5$  and  $-10$  kb of the transcriptional start sites (24.6%). It remains possible that some of these distal EREs may be located closer to another gene, or even within an open reading frame, accounting for their conservation.

To investigate whether location of EREs in coding sequences (CDS) may account for their conservation, we characterized the position of these elements for a subset of conserved EREs, *i.e.* those that were identical in sequence between the two orthologs (Table 2). A total of 41 elements were found in the vicinity of 47 genes. Of these elements, 14 were located fully and four were found partly in a CDS (Table 2 *bottom* and *middle*, respectively), whereas 23 were not found in any annotated open reading frames (Table 2, *top*). More than half of these (12 EREs) were located between  $-1$  to  $+1$ , another seven between  $-1$  and  $-10$  kb, and another four between  $+1$  and  $+5$  kb. Thus these results indicate that EREs that are conserved independently of their presence in a CDS are more likely to be found close to the 5'-end of mRNAs, although some elements are still located at several kb kilobase pairs from the start sites. Furthermore, the strong conservation of these elements, which is unlikely to result from chance alone, may indicate a role in the regulation of the neighboring genes.

Three known E2 target genes were present in the set of genes containing perfectly conserved EREs. The EBAG9 and COX7A2L genes contain previously identified EREs (Table 1). The fibroblast growth factor (FGF) 9 gene is also a known E2 target (43), although the presence of a near-consensus ERE in the proximal promoter was not previously reported. FGF9 mediates the proliferative action of estrogen on stromal endometrial cells (43). It also plays a role in glial cell development (44) and testicular embryogenesis (45). Its functional inactivation in mouse leads to male-to-female sex reversal (45). Interestingly, several other genes containing fully conserved EREs in their flanking sequences (Table 2) are linked to testicular function. TESK1 is expressed in testicular germ cells in a developmentally regulated manner and is thought to play a role in spermatogenesis around the stages of meiosis and/or early spermiogenesis (46, 47). KHDRBS3 (T-STAR/ETOILE) is a SAM68 homolog that is ex-



**Fig. 2.** Distribution of EREs in the Human and Mouse Genomes

A, Distribution of consensus EREs on human chromosomes. The percentage of nucleotides in individual chromosomes is plotted, along with the percentage of total response elements found per chromosome. B, Distribution of consensus EREs on mouse chromosomes. C, Distribution of EREs found between  $-10$  and  $+5$  kb of mRNA 5'-ends. The ratio between the number of EREs found and the expected number assuming a random distribution of these elements in the  $-10$  to  $+5$  interval was calculated for consecutive 1-kb segments of flanking sequences in the human (dark bars) and mouse (gray bars) genomes. For the elements conserved between the two genomes (white bars), the distribution was characterized only between  $-8$  to  $+3$  kb in order not to introduce a bias in the 2-kb constraint in relative distances between the two species.

pressed primarily in the testis and interacts with RBM, an RNA-binding protein implicated in spermatogenesis (48). FGF8 is an androgen-induced gene expressed

in testes specifically in spermatogonia during fetal d 16–17 (49). Finally, RNF14 (ARA54) is an androgen receptor coactivator expressed in testis and prostate

**Table 2.** EREs with Identical Sequences in Human and Mouse Orthologs

Human		ERE Sequence	Hs Dist.	Mm Dist.	Diff. Dist.	Diff. Dist.	Diff. Dist.
Gene Name*	UniGene #		ERE-mRNA	ERE-mRNA	Mm-Hs ERE-Gene	Mm-Hs ERE-mRNA	Mm-Hs ERE-CDS
<b>EREs located in a non-coding sequence (CDS)</b>							
HOXD13	Hs.152414	tGGTCAAATGACCC	-8865	-8719	146	146	257
KHDRBS3	Hs.13565	AGGTCAATGATGcCCA	-7491	-6925	552	566	724
LDB1	Hs.26002	GGGTCACTTTGACaC	-5679	-5682	5869	3	520
RNF14 <sup>1</sup>	Hs.170926	AGcTCAAGTTGACCC	-5410	-6671	3522	1261	532
HOXC12	Hs.381267	AGGTcTtTCTGACCT	-5201	-5113	88	88	88
PCDH12 <sup>1</sup>	Hs.115897	GGGTCAACTTGAgCT	-4640	-5554	872	914	10
KIF24 <sup>2</sup>	Hs.201179	tGGTCAGACTGACaT	-2923	-3246	323	323	7425
PDE8A	Hs.78746	ctGTcAGTGTGACCC	-2583	-1914	799	669	674
NDRG2	Hs.243960	GaGTcATCCTGACCC	-1347	-1900	178	553	21
TESK1	Hs.79358	GGGTcACAATGACtA	-991	-981	1457	10	260
NKX6-1	Hs.347185	GGGTcAGTTTgGcCa	-963	-410	353	553	82
PHF5A <sup>3</sup>	Hs.273234	GGGaCgCCTGACCT	-659	-807	148	148	153
SLC10A2	Hs.194783	ctGTcACTTTGACCT	-382	-753	542	371	177
FGF9	Hs.111	tGGTCATtCTGAtCT	-204	-237	2338	33	6
<b>EBAG9</b>	Hs.9222	<b>GGGTcAGGGTgACCT</b>	6	-4886	226	4892	5816
FGF8	Hs.57710	GGGaCgGCGTGACCC	67	153	128	86	67
CNNM4	Hs.175043	tGGTCAACGTGAgCC	215	57	158	158	42
ACO2 <sup>3</sup>	Hs.300463	AGGTCAAGGcGtCCC	219	203	122	16	2
COL4A2	Hs.407912	AGGTgAGAGcGACCC	243	284	41	41	26
EDG2	Hs.75794	AGGTcAGTgGcCCC	257	432	518	175	16676
<b>COX7A2L</b>	Hs.423404	<b>GGGTcAAGGTgACCC</b>	381	336	7812	45	16
UBE2R2	Hs.11184	AGGgCAGGGTgACCT	755	715	279	40	20
NFKBIA	Hs.81328	AGGTcTtTATGACCC	1233	1107	29	126	89
NR1D1	Hs.276916	GgTtCACCCCTGACCa	2314	1673	88	641	89
NUDT2 <sup>2</sup>	Hs.429142	AtGTcAGTCTGACCa	2617	2981	364	364	2470
HNRPDL	Hs.372673	GtGTcACCCCTGACCa	4639	3226	518	1413	957
<b>EREs located partially in a coding sequence (CDS)</b>							
B4GALT7	Hs.54702	AGGTcATCCTGgCCC	-6523	-5409	1105	1114	1122
SIRT7 <sup>4</sup>	Hs.184447	GGGTtATGAcGACCC	-5012	-4845	378	167	2786
SLC25A12	Hs.353282	cGGTCAAGGTGACtC	27	77	216	50	0
CD7	Hs.36972	AGGTcAGTGTGAgCC	1313	1751	357	438	385
<b>MAFG<sup>4</sup></b>	Hs.252229	<b>GGGTtATGAcGACCC</b>	4516	9	969	4507	0
<b>EREs located in a coding sequence</b>							
DEF6	Hs.15476	AGGTcAGCCTGtCCC	-4108	-4746	652	638	651
ARHGAP4 <sup>5</sup>	Hs.3109	AGGTcAGCGaGACCa	-3795	-5798	1885	2003	1961
ZNF142 <sup>6</sup>	Hs.80526	cGGTcAGCCaGACCC	-2345	-2383	5	38	728
GPR73L1	Hs.375029	tGGTgATTATGACCT	103	94	3818	9	9
ENDOG	Hs.420106	GGGcCgGCTGACCC	170	64	473	34	140
EDN3	Hs.1408	GgTtCACAGTgACCT	220	376	333	106	0
SFRS2	Hs.73965	tGGaCAACCTGACCT	221	219	595	2	0
RARG	Hs.1497	GGGcCAGCCTGACCT	288	4880	232	4592	0
TPBG	Hs.82128	tGGTgAGCCTGACCT	820	2324	448	1504	18
FZD6	Hs.114218	GGGTcATTATGACCa	1355	270	176	1085	0
PAX9	Hs.132576	GGGTcATTAcGACtC	1603	1309	267	294	94
AMBP	Hs.76177	AGaTCAGCATGACCa	1692	1545	147	147	140
BCS1L <sup>6</sup>	Hs.150922	GGGTcTGGCTGACCG	1847	2020	448	173	65
PRSS8	Hs.75799	AGGTcAGCATcACCT	2528	2209	268	319	199
APIG2	Hs.343244	tGGcCAACCTGACCC	4610	3756	474	854	98
<b>ARD1<sup>5</sup></b>	Hs.433291	<b>AGGTcAGCGaGACCa</b>	4961	4916	122	45	100

Human and mouse EREs with identical sequences were selected from the compilation of EREs located in known human (Hs) and mouse (Mm) orthologs with less than 2 kb difference in either their respective distances to the beginning of genes, mRNA, or coding sequences (see supplemental data for a full list). Elements that are fully conserved in sequence in the two orthologs were further analyzed to determine whether they are part of an annotated CDS (*bottom*) or not (*top*). Four additional elements were overlapping a CDS in at least one species (*middle*). Note that some elements are listed twice, as they are found in the vicinity of two genes and are shown in the orientation corresponding to each gene. Number pairs identify identical EREs. Elements in *bold* are known EREs.

\*, Mouse gene names are similar to the human names except for NDRG2 and ZNF142, whose counterparts are Ndr2 and Zfp142, respectively.

(50). Although estrogenic regulation of these genes remains to be demonstrated, these observations are noteworthy in view of the fact that estrogen deficiency in aromatase knockout models or genetic ablation of the ER $\alpha$  gene leads to defects in spermatogenesis and male sterility (51–53).

### Proximal and Distal EREs in Known Estrogen-Responsive Genes

To assess the potential of EREs found in this screen to bind ERs, we first compared our list of elements lying between  $-10$  and  $+5$  kb of the 5'-ends of known genes to published data on E2-up-regulated genes identified through expression studies in different human target tissues. This generated a list of 345 elements close to 236 genes (Table 3). Several of these genes were identified from a gene array experiment performed in the presence of cycloheximide, suggesting direct regulation (54). Interestingly, several promoters already shown to contain functional EREs were found to include additional elements, sometimes located more distally (Table 3; see also selected elements in Table 1). When assayed for binding to ER $\alpha$  in gel shift assays, several of these novel elements bound similarly or even better than those previously characterized (Fig. 3A, OVGP1, CTSD, and TERT). Of interest, the mouse ortholog of the CTSD gene did not contain a near-consensus element corresponding to the known human proximal element, but our search identified a new element located 8 kb upstream that is conserved between human and mouse. Another example of a gene containing conserved distal EREs is the EFP/ZNF147 gene. Our screen (performed in this case with a larger cutoff) identified a conserved imperfect element in the 3'-untranslated region of the mouse and the human orthologs, different from the consensus ERE previously reported in the human gene (Table 1). The presence of distal elements in E2-regulated genes suggests that they may participate in the estrogenic regulation of these genes.

Some estrogen-inducible genes for which EREs had not been characterized were found to contain several high-affinity elements. For instance, the GREB1 (gene regulated by estrogen in breast cancer) gene contains three consensus EREs located at  $-1.5$  kb,  $-9.5$  kb, and  $-21$  kb (Table 1). In addition, the human CASP7 gene was found to contain seven tandem repeats of a near-consensus ERE within the proximal 500 bp (Table 1). The presence of multiple elements raises the possibility of synergism at the level of either DNA binding or transcriptional activation in the regulation of these genes by estrogen and may suggest propagation of chromatin changes induced by recruitment of ER coactivators over a large distance.

### Functional Analysis of Newly Identified EREs

To assess whether EREs selected among those found in the promoters of E2-responsive genes (Table 1,

bottom) bind ER $\alpha$  *in vitro* with the predicted high affinity, gel shift assays were performed with elements in their natural context (15 bp core with 6 bp of flanking sequences; Fig. 3B). Although flanking sequences slightly modulated binding compared with the VitA2-derived elements carrying the same core ERE sequence, all elements were found to bind ER $\alpha$  efficiently. Chromatin immunoprecipitation (ChIP) experiments were performed next to monitor *in vivo* recruitment of hER $\alpha$  on the newly identified EREs. These experiments were conducted in ER $\alpha$ -positive MCF7 cells, ER $\alpha$ -negative MDA-MB231 cells, or MDAMB231 cells stably transfected with hER $\alpha$  (MDA::hER $\alpha$ ). As positive controls for ER $\alpha$  recruitment, both the pS2/TFF1 and complement component 3 (C3) elements (Table 1) were used and, as expected, demonstrated E2-dependent recruitment of ER $\alpha$  on their proximal promoters (Fig. 4). We investigated binding of ER $\alpha$  to 14 EREs found in 10 genes known to be regulated by estrogen in breast cancer cells (ADORA1, CASP7, CTSD, GAPD, GREB1, IGFBP4, LY6E, NRIP1, SCNN1A, TERT; Table 1 and references within). In the two ER $\alpha$ -expressing cell lines, E2-induced ER $\alpha$  binding was observed on 13 of 14 of the elements (which include both conserved and nonconserved EREs; see Table 1), except for the GAPD ERE where binding was restricted to MCF7 cells (Fig. 4). No binding was observed in the parental MDA-MB231 cells, or with preimmune rabbit IgG, on any of the promoters tested. Consistent with the published regulation of these genes by estradiol in breast cancer cells, association of the fragments of genomic DNA around the transcriptional start sites with the TATA box binding protein (TBP) and the phosphorylated polymerase II (P-PolII) was induced in the presence of E2 (Fig. 4). Notably, in addition to the proximal elements (ERE2) found in the CTSD and TERT genes, both upstream elements (ERE1) bound ER $\alpha$ . Binding of both the GREB1 EREs at  $-9.5$  kb (ERE2) and at  $-1.5$  kb (ERE3) was also observed, but the most upstream ERE ( $-21$  kb, ERE1) did not bind despite its consensus ERE sequence. This may suggest that this element was not accessible for ER binding, possibly because of chromatin organization.

Binding of ERs to EREs located in two genes that are not known to be estrogen targets in breast cancer cells was also investigated (GAD2, TSHB, Fig. 4). In contrast to results obtained with other ERE-containing promoters, ER $\alpha$  binding was not detected on the GAD2 ERE. Moreover, no binding of TBP or P-PolII was observed in the absence or presence of hormone. GAD2 catalyzes the synthesis of the inhibitory neurotransmitter  $\gamma$ -amino butyric acid, and its expression is restricted to neural tissues and pancreatic islets (55). Its regulation by estrogen has been described in rat and goldfish brain (56, 57). However, no expression of GAD2 was detected in breast cancer cells by RT-PCR analysis (data not shown). Absence of ER binding to these sites in breast cells may reflect limited access due to chromatin conformation. On the other hand,

**Table 3.** EREs Found in Up-Regulated Estrogen Target Genes

Gene	UniGene #	Pos.	ERE Sequence	REF	Gene	UniGene #	Pos.	ERE Sequence	REF	Gene	UniGene #	Pos.	ERE Sequence	REF	
<b>ADCY9</b>	Hs.20196	-3928	tGGTCATACTgACCT	132	<b>E2IG5</b>	Hs.5243	-8234	AGaTCAGGCTGACCa	95	<b>KRT7</b>	Hs.23881	2161	GGGCAATGTGACCC	116	
		1856	AaGTCACACTgAACCC	132	<b>EBAG9</b>	Hs.9222	6	<b>GGGTCAAGGTGACCT</b>	40			2659	tGGTCATTTGgAGcC		
<b>ADFP</b>	Hs.3416	147	AGGTCAGGTTgAACCa	133	<b>EDEM</b>	Hs.154332	-7338	tGGTCAGTGTGaaCC	99	<b>KRTHB3</b>	Hs.182506	-8336	GGGTCAcAGaGACCa	116	
<b>ADORA1</b>	Hs.77867	-3824	AGGTCAGATgTcCCT	54	<b>EDG2</b>	Hs.75794	-7418	ctGTCAACCCTGACCC	133	<b>L3MBTL</b>	Hs.300863	3633	GGGTcCTTTGACCa	94	
		-1171	AGGTCAGGTTgAACCT				257	GGGgCgCACTGACCT		<b>LDHA</b>	Hs.2795	-1074	AGaTCAGCTGACCa	95	
<b>AGT</b>	Hs.19383	-10	GGGTCAGATgCtCCT	133			1826	GgATCACTCTTgAACCT				-265	AGGTcGTCTGACcC		
<b>AHSG</b>	Hs.324746	-3185	GGATCAAACTgAACCC	90	<b>EGFR</b>	Hs.77432	3406	AaGTCACCTTTgAACCT	100			3181	AGGTggCAGTgAACCT		
<b>AIM1</b>	Hs.422550	363	GGGTCAAGCCcAACCC	91	<b>EGLN2</b>	Hs.324277	-8489	GGTCACCTGcGACCT	97			4478	tGGTCAAATcACCT		
<b>AKR1C4</b>	Hs.177687	1657	GGGTCAATTTaACCa	91	<b>EGR3</b>	Hs.74088	2335	GGGgCgGGTTGACCC	93,94	<b>LOC91012</b>	Hs.458450	-5009	AGGTtgcAGTgAACCT	54	
<b>ALPI</b>	Hs.37009	-9620	tGGTCACCTgAACCT	133	<b>EIF5A</b>	Hs.310621	1913	AGGTCcGTGTGACCT	95			-882	AGGTcgcAGTgAACCT		
		-419	AGGTcTcGGCTGACCC				3296	AGGTCAAATTTgAGcC		<b>LTF</b>	Hs.437457	-1166	AGGTgAGCTGACCa	85	
		2170	AGGCaCAGCTGACCC		<b>ELAZA</b>	Hs.21	-7130	AGGgCAGAGTgAACCa	133			-979	AGGTcAGCTGACCT		
<b>ALPP</b>	Hs.284255	-6033	GgATCACAGcGACCC	92	<b>EPO</b>	Hs.2303	-1664	AGGTCATTTGcACCT	94	<b>LYGE</b>	Hs.77667	-9749	GGGTCAAGATgACCT	54	
<b>AR</b>	Hs.99915	-599	GGGTgAaATGACCT	93			2697	GGGaCAGGATGACCT				-298	cGGTCACCCcGACCT		
<b>ARHC</b>	Hs.179735	-9916	AGGTCACAGcCACCCT	91	<b>F12</b>	Hs.1321	-30	tGGTCACCTGcCACC	81			3400	AGGTCAGCCcCACCC		
		-9815	AGGcCAAGATgAACCa		<b>FBP1</b>	Hs.360509	4639	AGGcCAAGTcGACCC	91	<b>MAP1B</b>	Hs.103042	-2800	AGGTgAAATGACCa	93	
		-3315	GGTCACAGCTGACCC		<b>FBP2</b>	Hs.61255	112	GGGTCAAGGTgAGCa	101	<b>MATN1</b>	Hs.150366	-8045	GGGTCAAGAcCACCC	131	
<b>ART3</b>	Hs.24976	-9809	GGGTCAcAGCaAACCT	94	<b>FBP2</b>	Hs.284244	-3472	AGGTCACAGTgAACCC	102	<b>MGC8407</b>	Hs.145156	-7041	AGGTCAGGTTgAACCT	54	
<b>ASS</b>	Hs.160786	585	GGGTgACTCTGACCT	95			4284	AGGTggcCCTGACCC		<b>MJD</b>	Hs.149756	-518	AGaTCAGCTGACCa	133	
<b>ATP2B2</b>	Hs.89512	-2600	GGGTCAATgTcCACCT	94	<b>FGF9</b>	Hs.111	-204	tGGTCATTTCTGAcCT	43	<b>MMP12</b>	Hs.1695	-5653	AGcTCAAGCTGACCC	133	
		-358	GGGTCAAGGTgCtCC		<b>FHR-4</b>	Hs.194776	85	AtGTCAATTTCTGACCT	95,103			-3556	tGGTCATCTGACCT		
<b>AXIN1</b>	Hs.512765	-6019	tGGTCAGGAgAACCC	54	<b>FKBP4</b>	Hs.848	1065	AGGTCATCTTgAACCT	91	<b>MMP2</b>	Hs.367877	-2578	AGGTcTcTATGACCT	117	
		-5940	AGGTCAAGTgGAcTg		<b>FOS</b>	Hs.25647	-3411	AaGTCACCCCTGACCT	93,104			-2870	tGGTCATCTGACCT	118	
<b>B4GALT1</b>	Hs.396798	-3158	AGGTgAAGCTGACCC	54	<b>FOSL2</b>	Hs.301612	-7343	tGGTCAGGCTGACCT	91			2295	GGGTcTcTTGgAACCC	119	
		3242	AGGTCAcACTaAACCC		<b>FOXO1A</b>	Hs.170133	391	cGGTCAGTGTGACCC	133			3822	AGGTgATCTTgAACCC		
<b>BDKRB2</b>	Hs.250882	-3298	tGGTCtGTCTGACCT	133	<b>GPD</b>	Hs.80206	-59	GGTCcAAGCCgGCC	54	<b>MSX2</b>	Hs.89404	-9630	AGGTCAAGATGAcCa	54	
<b>BCL2</b>	Hs.79241	319	GGGTCAAGTgGACCa	80			4556	AGGTCAATGCTGAcT		<b>MTHFD2</b>	Hs.154672	-4241	GgTCACCTTgAACCT	91	
<b>BCL2L1</b>	Hs.84063	-6090	GGGTgATCTcGACCT	94	<b>GAB2</b>	Hs.30687	-3399	AGGTCAAGTGTGACCa	105	<b>MYBL2</b>	Hs.179718	3441	AGGTgAGCTGACCT	132	
<b>BICD1</b>	Hs.412020	929	AGGTCAcCCCTGAcCa	94	<b>GAL</b>	Hs.278959	-8992	tGGTCAGGCTGACCT	106	<b>MYBL3</b>	Hs.172674	-2740	GGGTcCAAGTgAACCT	94	
<b>BIRC3</b>	Hs.127799	-6658	AGGgCAATTTgAACCT	133			-4905	GGGTCACTTgGACCT		<b>NFATC3</b>	Hs.127674	-2740	tGGTCAGCTGAcCT	95	
<b>BIRC5</b>	Hs.1578	-6502	tGGTgACAGTgAACCT	132	<b>GAPD</b>	Hs.169476	-8031	AGGTgCAAGTgAACCC	88	<b>NME1</b>	Hs.118638	-5636	tGGTCAGACTGAcCT	120	
		4986	GgTCACCTGcAACCT				-5870	cGGTCcCCATGACCC		<b>NOS3</b>	Hs.446303	-4618	AGGTCAAGGcGTCC		
<b>BTEB1</b>	Hs.150557	-9843	AGGTCACTGcAACCT	132			-738	AGGaCACTGTGACCT				-1593	ctGGTCACCTTgAACCT		
<b>BUB1</b>	Hs.287472	-4500	AGGTCAATGgGACCT	132	<b>GAS6</b>	Hs.437710	1780	GGGTCAcCCcCACCC	133	<b>NPM1</b>	Hs.411098	-1876	AGGTCAAGCTGgACCT	121	
		-3360	AGGcCAAGCTGACCa		<b>GCH1</b>	Hs.86724	-3702	cGGGCAAGTGTGACCC	133	<b>NPR2</b>	Hs.78518	-6835	AGGTcGTCTTgAACCT	133	
<b>C11orf8</b>	Hs.432000	4209	AGGTgATATTgAACCa	133			3788	AGGTCAAGATcACCa				-2519	AGGaCACTGgACCT		
<b>C3</b>	Hs.284394	-9210	GGGTcTcTTGgAACCC	133	<b>GHRHR</b>	Hs.767	-3049	tGGcCAGGCTGACCT	133			705	GGGTcGTCTGcCC		
		-226	GGGTCAAGCCcAACCT				4741	AGGTCAATGgGACCa		<b>NR4A1</b>	Hs.1119	3478	tGTCTACTTgAACCT	94	
<b>CALCR</b>	Hs.640	927	GGGTCAAGTgGAcg	132			-1619	tGGTCAGGCTGcCACC		<b>NR4A3</b>	Hs.279522	-1929	GGGTCAAGGcGcCC	94	
<b>CALM2</b>	Hs.425808	-8603	cGGTCACCTGAcAACCT	95	<b>GNRHR</b>	Hs.73064	3727	GGGTCACTGATGACCa	107	<b>NRIP1</b>	Hs.155017	-706	<b>GGGTCACTTgAACCC</b>	54,91	
		1287	AcGTCaAGAcGACCT		<b>GREB1</b>	Hs.438037	-9517	<b>GGGTCACTTgAACCC</b>	89	<b>NUCB2</b>	Hs.423095	-857	GGGTtgcATTGACCC	91	
<b>CASP7</b>	Hs.9216	-486	GGGTCAAGGTGAcAACCT	87	<b>GTF2I</b>	Hs.408507	-8553	GGGTCACTTgAACCT	91	<b>OVGP1</b>	Hs.1154	-156	GAAGTCACAGTgAACCC	74	
		-392	GGGTCAAGGTGAcAACCT				-6471	AGaTCAGGCTGACCa				200	GGGTcCTCTGACCT	133	
		-312	GGGTCAAGGTGAcAACCT		<b>H11</b>	Hs.111676	-7364	AGGTcTcTTGgAACCT	87	<b>OXT</b>	Hs.113216	-2596	AGGTCAAGTGTGACCT	79	
		-272	GGGTCAAGGTGAcAACCT		<b>H2AFZ</b>	Hs.119192	2777	ctGTCAAAATGACCT	95			-2465	AGGTCAAGCTGgACCC		
		-232	GGGTCAAGGTGAcAACCT		<b>H3F3A</b>	Hs.181307	-4907	AGGcCAGCCTGACCa	95	<b>P2RY6</b>	Hs.16362	-4581	AGGTCAAGCTGgACCa	94	
		-195	tGGTCAGGTTgAACCT		<b>HM13</b>	Hs.444601	2754	GGGTCAAGGTGcCCa	94	<b>PA2G4</b>	Hs.374491	-5274	GgTCACAGTgAACCC	95	
<b>CASP8</b>	Hs.243491	1374	AGGTCACCTTTgAACCT	133	<b>HMGB1</b>	Hs.434102	-5191	AGGTCACTGcGACCT	108	<b>PCNA</b>	Hs.78996	-9730	tGGTCAGGCTGcCCT	100	
<b>CAVI</b>	Hs.74034	-6690	tGGcCAGGTTgAACCT	95	<b>HMOX2</b>	Hs.284279	-6954	AGGTCAAGAcTcAACCT	109	<b>PDE4B</b>	Hs.188	4409	GGGTCAAAATcAACCT	132	
		2616	GGGTCAAGCTGcCCT				-2454	GGGTcCAAGTgAACCT		<b>PDE4C</b>	Hs.437211	-2035	GgTCACAGTgAACCT	94	
<b>CBFA2T3</b>	Hs.110099	-2378	GGGTCAAGCTGAcGcC	132	<b>HPCAL1</b>	Hs.3618	-6710	AGGTcTcTTGgAACCT	133	<b>PDK4</b>	Hs.8364	560	cGGTCACAGcGACCC	133	
<b>CCBP2</b>	Hs.24286	-1509	AGGTcTcTTATgAACCT	132	<b>HPS1</b>	Hs.404568	2429	GGGgCAGCCTGACCa	133	<b>PKMYT1</b>	Hs.77783	-3298	AGGTCAcCAAGAcCT	132	
<b>CD33</b>	Hs.83731	82	GGGTCAAGCTGACCC	133	<b>HSPA8</b>	Hs.180414	-9233	AGGTcCgCAGTgAGcC	95			-722	tGGTCACAGcGACCC		
<b>CD34</b>	Hs.374990	-8306	AGGTCAAAATcAACCC	94			-2702	GGTCACCTGcGACCT		<b>POLA2</b>	Hs.201897	-2268	AGGTCAAGGAgAACCT	132	
<b>CD69</b>	Hs.82401	-9834	GGTCAACATGAcTg	94	<b>HSPB1</b>	Hs.76067	-7227	-6805	GGGcCAATTTGACCC		<b>PPP2R4</b>	Hs.400740	-427	GGGTCAAGAcCACCC	122
<b>CD86</b>	Hs.27954	-7718	GGGTgGAGTgAACCC	133			1428	AGGgCAcACTGACCCg		<b>PRC1</b>	Hs.344037	-265	AGGTgCAGTgAACCT	87	
<b>CDC27</b>	Hs.406631	-6134	tGGTCAGGCTgGcCCT	91,97			4951	GGGTCAAGCTGgCtCC	95	<b>PRKARIA</b>	Hs.280342	-8067	AtGTCAATTTgAACCT	133	
<b>CDC6</b>	Hs.405958	2208	AGGTCACTTgAACCT	91,97	<b>HSPCA</b>	Hs.446579	-3795	AGGgCAATCTGACCa	95			1396	tGGTCAGTgAACCT		
<b>CDR1</b>	Hs.446675	-9550	tGGTCACCATcAACCT	94	<b>HSPD1</b>	Hs.79037	-4771	tAGTCAGTGTGACCT	101	<b>PRKCB1</b>	Hs.349845	1396	tGGTCAGTgAACCT	133	
<b>CEBPB</b>	Hs.99029	-3454	GGGTCAAAATTTgAACCa	91	<b>IDH2</b>	Hs.5337	-4929	AGTCACATGACCT	91			2434	GgGgCAAGTgAACCT		
<b>CITED2</b>	Hs.82071	2486	AGcTCACTGACCT	94	<b>IER3</b>	Hs.76095	-7195	AGTCACGcCCTGACCC	54	<b>PSMB4</b>	Hs.89545	-1786	GGGTcCgCAGTgAGcC	95	
<b>CNR1</b>	Hs.75110	-3061	GGGcCAGTGTGACCT	94			-5668	tGGgCAAAATTTgAACCT		<b>PTGER3</b>	Hs.527970	-5430	GgGaCAGAGTgAACCT	132	
		2628	AGGTCAAGATgAGCa		<b>IFRD2</b>	Hs.315177	1836	GGTCACCTGcGACCT	94	<b>PTMA</b>	Hs.459927	4361	AGGTcCgCAGTgAACCT	123	
<b>COL18A1</b>	Hs.413175	-7884	tGTCAAAATGACCC	133	<b>IGFBP4</b>	Hs.1516	-4124	cGGTCATGTGcCtCC	54,91	<b>PTPN2</b>	Hs.446126	-9369	AGGTcCgCAGTgAACCT	94	
<b>COMT</b>	Hs.240013	-8302	AGGTCACTCTGcCCT	96			273	cGGTCATGTGcCtCC		<b>PTPRO</b>	Hs.160871	-6656	AGGTcCgCAGTgAACCT	94	
		-1798	tGGcCACTGTGACCT		<b>IL1R2</b>	Hs.25333	-6432	GGTCACAGGTGACCC	94	<b>PTPRU</b>	Hs.19718	-5945	cGGTCCTTCTGACCT	94	
<b>COX7A2L</b>	Hs.423404	-5246	AGGTCAAGATgCCa	40	<b>IL8RB</b>	Hs.846	-2298	GGTCACCTGACCT	133			3505	tGGcCAGCTGACCT		
		381	<b>GGGTCACTTgAACCC</b>				3946	tGGTCAGCCgGACCC		<b>PTTG2</b>	Hs.511755	-3351	GgATCAAGCTGACCa	94	
<b>CP</b>	Hs.282557	-3500	AGGTCACTCTGAcTc	94	<b>INHBB</b>	Hs.1735	-8211	AaGTCACCAcGACCC	94	<b>PTX3</b>	Hs.2050	844	AGGcCAGCTGACCa	133	
<b>CPM</b>	Hs.334873	-2066	<b>AGGTCACTTgAACCC</b>	133			-3738	AGGcCAGCTTgAACCC		<b>QPCT</b>	Hs.79033	190	GGGTCAAGCTcAACCT	133	
<b>CRHR1</b>	Hs.417628	-7603	AGGTCAAGGTgGcCCa	94	<b>INPP5A</b>	Hs.408063	1410	AGGcCgTCTGACCT	133	<b>RAN</b>	Hs.10842	2869	GgTCACAGTgAACCT	95	
<b>CSPG2</b>	Hs.434488	-8225	GGGTgGAGTgAACCC	133	<b>IRS1</b>	Hs.390242	-6253	GGGTCAcCATTgGcCCT	110			3007	tGGTCAGCTGAcCT		
<b>CST4&lt;/</b>															

Table 3. Continued

Gene	UniGene #	Pos.	ERE Sequence	REF	Gene	UniGene #	Pos.	ERE Sequence	REF	Gene	UniGene #	Pos.	ERE Sequence	REF
<i>SLC29A1</i>	Hs.25450	4242	cGGTCACGTTGACCT	54	<i>TERT</i>	Hs.439911	-5663	GGGTCACTCTGACCC	124	<i>VDR</i>	Hs.2062	-3231	GGGTCACTTTGTCCC	127
<i>SLC7A5</i>	Hs.184601	4963	AaGTCAGAATGACCT	54,91			-2687	AGaTCAGCCTGACCa		<i>VEGF</i>	Hs.73793	-9667	AGGcCACTGTGACCC	132
<i>SLK</i>	Hs.105751	-3049	AGGTCACTGcaACCT	132	<i>TFE1</i>	Hs.350470	-392	tGGcCACCGTGACCT	91,133	<i>VTN</i>	Hs.2257	-4209	AGGTCAAGATGACT	87
<i>SMC2L1</i>	Hs.119023	-9528	AGGTCTTTGTGACCT	94	<u><i>TFE3</i></u>	Hs.82961	-8655	AGGTCTTTATGACCT	54,124	<i>VWF</i>	Hs.440848	-9547	AGGTCAAGcGAGCC	133
		-8678	tGcTCAGCTTGACCT				-4315	GaGTCAcAcGACCT	125	<i>WISP2</i>	Hs.194679	-2526	AaGTcGAGGTGACCT	97
<i>SNRK</i>	Hs.79025	-1342	AGGTcAGAGTGA <sup>c</sup> CC	94	<i>TFPI2</i>	Hs.438231	-4126	tGGTCATGTTACCT	54			-452	GGGTCAcAcCCACT	
<i>SNRPA</i>	Hs.173255	2000	AGGTcGcAGTGA <sup>c</sup> CT	54	<i>THBD</i>	Hs.2030	-2152	GGGTggACATGACCC	94	<i>WNT1</i>	Hs.248164	-9908	GGGTCAAGATGA <sup>c</sup> CT	128
<i>SOS1</i>	Hs.326392	-3457	tGGcCATGTTGACCT	94	<i>TNFRSF8</i>	Hs.1314	-6502	AGGTCAAAgGACCT	94	<u><i>WNT10B</i></u>	Hs.91985	3215	GGGTCAAGATGA <sup>c</sup> CT	129
<i>SP4</i>	Hs.2982	-1480	GGGTCACTTcCACCT	94			-2999	GGGTgACTCTGACCC		<i>WNT9B</i>	Hs.326420	1839	GGGTCACTGcaACT	130
<i>SPRY1</i>	Hs.436944	138	GGGTcAGCCaGACcG	94	<i>TOB1</i>	Hs.178137	-3159	AGaTCAGCTTGACCa	54			3736	GGGTtGCACTGACCC	
<i>SPRY2</i>	Hs.18676	1041	GGGTCAgCCcGAGcCT	94	<i>TOPBP1</i>	Hs.91417	-1262	tGaTCACCTTGACCT	133	<i>XPNPEP1</i>	Hs.390623	-799	AGGTtGcAGTGA <sup>c</sup> CT	94
<i>SSNA1</i>	Hs.18528	-8128	GGGTcGtGATGA <sup>c</sup> CC	107	<u><i>TP53</i></u>	Hs.408312	-1529	AGGTGgATCTTcCT	126	<i>XRCC4</i>	Hs.150930	-7225	AGGTtATCTGACCa	133
		-1829	cGGTCTcCCCTGACCC		<u><i>TPBG</i></u>	Hs.82128	-4705	tTGTCAAATGACCC	54	<i>ZDHHC4</i>	Hs.5268	9951	GGGTCACTTGCcCG	97
		3468	AGGTCAATTCTGA <sup>c</sup> g				820	tGGTgAGCCTGACCT		<i>ZNF17</i>	Hs.185796	3231	GgaTCATTGcGACCT	94
<i>STAG1</i>	Hs.138263	-4456	caGTCACATGACCT	133	<i>TPO</i>	Hs.71304	-609	caGTcATGGTGA <sup>c</sup> CT	94	<i>ZNF230</i>	Hs.193583	-9478	GGcTCACAGcGACCT	94
<i>STK6</i>	Hs.250822	3170	GGTCAATTccACCT	132	<i>TPX1</i>	Hs.2042	-7640	GGGTCACTTgAAcCa	133			82	GGGTcGcAAcGACCC	94
<i>SUOX</i>	Hs.16340	-7499	<b>AGGTCAcAGTGA<sup>c</sup>CT</b>	95			-3900	AGGTCTTTATGACCT		<i>ZNF75</i>	Hs.355015	-6059	AGGTCAATGATGA <sup>c</sup> Ca	94
		306	AaGTcAGTCTGACCC		<i>TRIM31</i>	Hs.493275	-288	AGaTCAGAATGACcG	133			-62	GGGTCAcATGACCa	
		1718	GGGTcAGGGTGA <sup>c</sup> CT		<u><i>TSHB</i></u>	Hs.406687	-4099	AGGTCAcGCTTGA <sup>c</sup> CaT	59	<i>ZNF9</i>	Hs.2110	2272	AGGTcGcAGTGA <sup>c</sup> CC	95
<u><i>TAC1</i></u>	Hs.2563	167	GGGTCAcCCcGcCC	94	<i>USF2</i>	Hs.454534	305	GGGcGcGGCTGACCC	97	<i>ZNF91</i>	Hs.8597	-5023	AtGTCAcAGTGA <sup>c</sup> CC	131
<i>TCF2</i>	Hs.408093	996	AGGTCAATGTGtCCg	94			2061	GGGTCCcCCCTGACCa						

The listed EREs were compiled by comparison with upregulated E2 target genes identified in gene expression studies as cited. The positions given are distances to the most upstream mRNA 5'-end for each gene (negative distances correspond to elements located upstream of the 5', and conversely). ERE sequences in *bold* correspond to consensus elements. *Underlined* genes contain EREs that are conserved in mouse (see supplemental data) according to criteria defined in *Materials and Methods*.

ER $\alpha$  bound to the TSHB ERE whereas no binding of TBP and P-PoIII was detected either on the reported start site (58) or on another site described in NCBI (National Center for Biotechnology Information) AceView (Fig. 4). Note that regulation of TSHB by E2 has been observed in mouse pituitary (59). It is possible that another transcriptional start site may be used in MCF7 cells, or that this gene is inactive in these cells despite ER $\alpha$  binding to upstream sequences.


Results from ChIP experiments demonstrate that it is possible to identify *bona fide* ER binding sites both in proximal and distal promoter sequences of E2 target genes, suggesting that the search for ER binding sites should not be limited to promoter sequences immediately upstream of the transcriptional start site. In addition, our results indicate that access to some high-affinity binding sites is restricted *in vivo*, possibly in a tissue-specific manner.

## DISCUSSION

In this study, our goal has been to define high-affinity *in vitro* ER binding sequences and to characterize the occurrence of these motifs throughout the human and mouse genomes. This approach differs from those of previous studies, which have aimed at characterizing a larger array of potential binding sites for ERs or nuclear receptors in defined stretches of genomic sequences (60, 61). These approaches are based on nucleotide frequency matrices constructed via compilation of the relatively small number of known natural response elements and can identify many variant sequences. Although the sensitivity of the detection can be low-

ered for screening of genomic sequences, these types of detection programs cannot be easily used for genome-wide studies (the maximal length of input sequences is ~100 kb for Dragon ERE Finder version 2.0 and 30 kb for the NUBIScan program). On the other hand, we chose to identify only high-affinity binding sites in a genome-wide approach to determine their distribution with respect to transcriptional start sites, their conservation between the mouse and human genomes, and their functionality as receptor binding sites *in vivo*. Our choice of elements was based both on functional validation of variant EREs by *in vitro* binding assays, and on the variations observed in known near-consensus sequences. Although not within the scope of this study, our functional characterization of EREs both *in vitro* and *in vivo* is also expected to contribute to the development of refined nucleotide frequency matrices for the detection of a wider range of elements in genomic sequences of interest.

Our screen identified a large number of EREs (71,119 in the human genome, or about one in every 43 kb of genomic DNA). Not surprisingly, the frequency of ERE occurrence was found to be highly dependent on their sequence. For instance, elements containing CG dinucleotides are drastically less represented than other EREs. CG dinucleotides are represented at a frequency of about 0.8% in the genome, which is five times less than the expected frequency based on the typical fraction of Cs and Gs (42). Elements containing two CG dinucleotides are found at only about 1–2% of the number of consensus EREs, which do not contain CG dinucleotides except possibly in the spacer. On the other hand, consensus EREs are slightly more represented than the expected fre-



**Fig. 3.** *In Vitro* Binding of ER $\alpha$  to EREs Identified in This Study


A, Relative binding of hER $\alpha$  to known and newly characterized EREs in estrogen target genes. B, Binding of hER $\alpha$  to the novel EREs characterized through genomic screening. Binding is expressed as the percentage radioactivity of specifically bound probe vs. bound plus free probe.

quency in random sequences (122% in human and 150% in mouse).

The sequence bias for some of the elements and the observation that some high-affinity EREs are found in tandem repeats precluded evaluation of which proportion of near-consensus EREs are under positive selective pressure, as could be expected if they mediate important regulatory roles. However, it was possible to evaluate the relative distribution of EREs in the vicinity of human or mouse genes. We have calculated that the number of EREs found in the human genome in the  $-1$  to  $+2$ -kb region around the 5'-end of mRNAs exceeds the number of elements expected from their frequency in the genome by 64%. It is unclear whether this represents conservation of elements found in the vicinity of transcriptional start sites, or bias for undetermined causes. A contributing factor may be the increased GC content in CpG islands, which are associated with the 5'-end of genes. Consensus EREs have an average GC content varying between 40 and 73% (depending on the identity of the variable bases). For most sequences, this is higher than the genome-wide average of 41%, but compatible with the 60–70% average in CpG islands (42). It is surprising, however, that the main peak of ERE representation is in the 0 to  $+1$ -kb region around the 5'-end of mRNAs both in human and mouse. Although the basis for this observation is unclear, it is worth noting that only the most 5'-mRNA start site for each gene was taken into consideration in this representation. Thus, some of these EREs may regulate promoters of downstream initiation sites.

We performed next a direct comparison of elements found in human and mouse orthologs to assess the fraction of total EREs that is conserved in the two species. Of the 9944 known orthologs (Mouse Genome Informatics database), 660 contained one or several conserved EREs at similar relative positions in the 5'-flanking sequences, *i.e.* at 2 kb from each other (708 conserved elements in total). This corresponds to about 1% of total elements in the human or mouse genome. Note that our criteria for conservation are relatively stringent, including both limited sequence variations (no more than two differences from consensus) and positional constraints (relative positions of EREs not further apart than 2 kb). Other possible sources of under-representation of conserved EREs are the incomplete identification of human/mouse orthologs, and the lack of systematic annotation of the mRNAs 5'-ends in the human and mouse genomes. Nevertheless, we have estimated that there is an approximately 74% overrepresentation of EREs compared with chance occurrence of these elements in both the human and mouse orthologs within 2 kb of each other (708 vs. 407 elements; see *Materials and Methods*). This overrepresentation suggests functional conservation of EREs throughout evolution, although we cannot rule out that functions unrelated to recruitment of ERs may contribute to this conservation (see below). The distribution of the conserved EREs was similar to that of total EREs in the vicinity of human or mouse genes but displayed a more marked concentration in the vicinity of the transcriptional start sites (see Fig. 2C). Interestingly, the percentage of conserved elements dropped markedly upstream of  $-5$  kb, suggesting that upstream EREs are less likely to be conserved than elements closer to the initiation site, albeit these EREs still represent 24% of the total number of conserved elements between  $-10$  and  $+5$ .

Apart from conservation due to functional importance, the most likely reason for preservation of an ERE is its location within the coding sequence of a gene. This parameter might contribute to the overrepresentation of EREs located downstream of the initiation start sites. In addition, some upstream elements may also be found in the coding sequences of other genes. The possible contribution of coding sequences in preserving ERE motifs in the human and mouse genomes was examined in the extreme case of EREs found to be totally conserved in sequence between the two species, including the Pu/Py and spacer base pair. Of 41 distinct EREs flanking 47 genes, 14 were found in coding sequences in both species, and four additional elements overlapped a CDS. It is unclear whether these elements could function as binding sites *in vivo*. Binding of yeast transcription factors such as Gcn4, Sbf, Mbf, and Rap1 to elements within open reading frames occurs reportedly less frequently than in promoter sequences (62–64) and, in the case of Gcn4, results in recruitment of histone acetyltransferase and SWI-SNF coactivator complexes, but not of the Mediator complex (64). Finally, 23 EREs were not



**Fig. 4.** *In Vivo* Binding of Human ER $\alpha$  to EREs in ER-Positive Breast Cancer Cells

Interaction of hER $\alpha$  with selected EREs in the absence or presence of estrogen was investigated by chromatin-immunoprecipitation assay in ER $\alpha$ -negative MDA-MB231 (MDA) cells, in ER $\alpha$ -positive MCF7 cells, or in MDA-MB231 cells stably transfected with an expression vector for hER $\alpha$  (MDA::hER $\alpha$ ) and treated or not with E2 for 2 h. Fragments containing putative EREs were immunoprecipitated from formaldehyde-fixed chromatin preparation with antibodies against hER $\alpha$ , TBP, or phosphorylated polymerase II (P-PolII), or with preimmune rabbit IgG. A separate fragment spanning the transcription start site was used for PCR amplification when the start site was situated at more than 400 bp of the ERE. Whenever available, experimentally mapped transcription start sites were included in the +1 fragments. Experiments were performed two to three times and a representative result is shown.

found in coding sequences in either species. Interestingly, more than half of these EREs (12 elements) were located between  $-1$  and  $+1$  kb of the transcriptional start site, including eight elements between  $0$  and  $+1$  kb. Therefore, although the presence of EREs in coding sequences may account, in part, for element conservation, it does not explain the large proportion of elements found immediately after the annotated transcriptional start site. Of interest in this regard, a recent publication indicated that an important fraction (40%) of NF $\kappa$ B *in vivo* binding sites in chromosome 22 is located in intronic sequences (65).

Even though EREs appear less represented and/or conserved when located farther upstream of the transcriptional start site ( $-1$  to  $-10$  kb), our results suggest that they may contribute to estrogen target gene regulation. Indeed, some of these distal EREs are conserved between the human and mouse genomes and bind ER $\alpha$  *in vivo*, as demonstrated by our ChIP experiments. These observations validate the choice of the  $-10$  to  $+5$ -kb window around transcriptional start sites used in this study to identify potential ER binding sites. However, the frequency of near-consensus EREs found within this range strongly suggests that not all of these elements mediate transcriptional regulation of neighboring genes in a given cell context. It is unclear at this point whether access to some of these elements is restricted, or whether bound receptors may be unable to transactivate neighboring genes. The number of EREs in bulk genomic DNA also indicates that if all elements were accessible, binding sites would likely outnumber the molecules of receptor dimers in estrogen target cells. Indeed, the number of estrogen binding proteins in rat uterine cells was estimated via either biochemical or autoradiographical methods to vary between 5,000 and 30,000 molecules per cell (66–69). Large-scale studies of transcription factor binding sites using ChIP assays have also indicated that the number of *in vivo* binding sites for different transcription factors in the genome is high. For instance, in ChIP experiments performed in HeLa S3 cells, 15% of the genes in chromosome 22 were found to contain functional NF $\kappa$ B binding sites within 10 kb (65). In addition, 11% of the promoters were found to contain one or several high-affinity *c-myc* binding sites, suggesting competition between target sites in chromatin for limiting amounts of Myc protein levels (70). Alternatively, another possibility that arises from these observations is that stochastic and/or dynamic binding of transcription factors may allow usage of a larger number of binding sites.

We are aware that the total number of potential ER binding sites may be much higher than reported here. Elements not included in our search may represent good binding sites *in vivo*, including those that display a relatively low affinity *in vitro*. Whereas the compiled list of EREs is clearly not exhaustive, our ChIP experiments support the notion that the near-consensus EREs identified in estrogen-target genes represent likely binding sites *in vivo* (13 of 14 elements bound).

Nevertheless, access to some of these elements may be restricted irrespective of their strength as ER binding sites *in vitro*. Neither a perfect ERE located within about 20 kb of the transcriptionally active GREB1 estrogen target gene, nor a near-consensus ERE located in the nontranscribed GAD2 gene were bound in ChIP experiments. Although results obtained in two breast cancer cell lines were very similar, it will be of interest in future studies to examine further how binding site recognition and coactivator recruitment are affected by cellular context. The future availability of large-scale gene expression studies performed in different tissues will allow us to expand the list of known E2 target genes and to determine whether the near-consensus EREs in their flanking sequences are bound in a tissue-specific manner. In addition, our data will facilitate future studies comparing the patterns of coactivators recruited by distal/proximal elements. For instance, it is possible that upstream EREs would recruit histone acetyltransferase and/or SWI/SNF complexes, resulting in long-range opening of chromatin and facilitating access of enhancer proteins to far upstream flanking sequences, whereas only proximal promoter sequences may be able to recruit mediator complexes. Alternatively, chromatin loops may allow upstream elements to participate in the recruitment of the basal machinery on the transcriptional start site. It is our hope that the database of high-affinity EREs derived from this study (URL: <http://mapageweb.umontreal.ca/maders/eredatabase/>) will prove a useful tool for the characterization of primary E2-regulated genes in various human and mouse target tissues and will ultimately enhance our understanding of the molecular mechanisms underlying the physiological actions of estrogens.

## MATERIALS AND METHODS

### Bioinformatics

The algorithms developed (Nagai, Y., V. Bourdeau, and S. Mader, in preparation) enable a search of the NCBI fasta and gbs files of the Human Genome (Built 33; June 6, 2003) or of the Mouse Genome (Built 30; March 11, 2003) for a specified group of sequences and extract the positions of matching motifs in the genome contigs as well as the coordinates of the surrounding genes, mRNAs, and CDS within a preset cutoff distance of each motif. The programs, written in C, were run on an SGI Origin 2000 with 32 CPUs IP 27, R10000, 300-MHz processor (16 Go) using UNIX IRIX 6.5. Results presented in this article were generated using a cutoff of  $-10$  to  $+5$  kb of the mRNA 5'-ends (database available at <http://mapageweb.umontreal.ca/maders/eredatabase/>). Statistics for the total number of EREs occurring in the genomes were derived from lists of elements generated before the cutoff was applied. The total number of consensus EREs in the human genome was 891, and the number in the mouse genome was 923. Expected frequency in random DNA sequences was calculated as the total number of base pairs in the genome divided by the frequency of occurrence of a sequence with specified base pairs at 10 positions and two base pair choices at two positions ( $3,069,334,246/4^{11} = 732$

EREs in the human genome;  $2,578250392/4^{11} = 615$  EREs in the mouse genome).

Conserved EREs were identified as elements present in both human and mouse gene orthologs (listed at the Mouse Genome Informatics database) at distances comprised between  $-10$  to  $+5$  kb from their respective mRNAs 5'-ends, and differing by less than  $\pm 2$  kb. Because in numerous instances transcriptional start sites are mapped at the ATG codon in at least one species, or at the 5'-end of the gene for alternative upstream start sites, we have included EREs present in orthologs that were distant from each other by more than 2 kb when positions were calculated with respect to mRNAs 5'-ends, but less than 2 kb with respect to gene 5'-ends or initiator ATGs to minimize the underrepresentation of conserved EREs due to differential annotation in the human and mouse genomes. For example, the EBAG9 gene element, which is perfectly conserved in sequence, would not be selected on the basis of the distances to the 5'-end of mRNA because the mouse transcriptional start site was annotated at the ATG, but was included due to similar location with respect to the annotated 5'-end of the genes. Note that the 5'-end of the mRNA now coincides with the 5'-end of the gene in the most recent version of the mouse genome (Build 32).

The probability of an ERE to be found by chance in both the human and mouse orthologs was calculated by multiplying the probability of finding an element within  $-10$  to  $+5$  kb of the start site of one gene (14,074 elements in that window of the human genome/34,699 total genes) by that of finding an ERE in a 4-kb window ( $\pm 2$  kb) of corresponding sequence in the other species (12,828 elements  $\times$  4 kb/33,914 total mouse genes  $\times$  15 kb) and by the total number of orthologs (9,944 gene pairs) giving 407 expected elements.

### Cell Culture

Hela cells were maintained in DMEM (Wisent, St-Bruno, Québec, Canada) supplemented with 5% fetal bovine serum (FBS, Sigma, Oakville, Ontario, Canada). Cells were switched 3 d before experiments to medium without phenol red containing charcoal-stripped serum. For gel shift assays, Hela cells were electroporated ( $10^7$  cells, 0.24 kV, 950  $\mu$ F in a Bio-Rad Gene Pulser II apparatus; Bio-Rad Laboratories, Mississauga, Ontario, Canada) with 80  $\mu$ g expression vector (pSG5-ER $\alpha$ , pSG5-ER $\beta$  or parental vector alone). Note that pSG5-ER $\beta$  was generated by subcloning the open reading frame of hER $\beta$  (71) from pCMVSPORT-ER $\beta$  (a kind gift from Dr. T. Willson, Glaxo Wellcome, Inc., Research Triangle Park, NC) into the *Bam*H1 site of pSG5 (72) by PCR amplification. Cells were treated with 25 nM E2 (Sigma Chemical Co., St. Louis, MO) 1–2 h before harvesting (48 h post transfection). Whole-cell extracts were prepared by three freeze-thaw cycles in gel retardation buffer as previously described (73).

For ChIP experiments, MCF-7 and MDA-MB231 cells were grown in DMEM (Sigma) supplemented with 10% fetal calf serum (Sigma). The medium was changed to phenol-red free DMEM supplemented with 2.5% dextran-charcoal treated fetal calf serum 48 h before hormone addition and replaced each 24 h. The MDA::hER $\alpha$  cell line stably expressing hER $\alpha$  was generated from hER $\alpha$ -negative MDA-MB231 cells by transfection of pCDNA3.1/Hygro-hER $\alpha$  (25).

### Gel Shift and ChIP Assays

For gel shift assays, whole-cell extracts expressing ER $\alpha$  or ER $\beta$  or control extracts from cells transfected with the parental pSG5 vector were diluted to 120 mM KCl and assayed for binding to  $^{32}$ P-labeled, double-stranded oligonucleotide probes (50,000 cpm/sample) as described previously (73). Radioactivity associated with bound or free probe was quantified using a Molecular Imager FX with the Quantity One software (Bio-Rad).

For ChIP assays, chromatin was cross-linked using 1.5% formaldehyde for 5 min at 37 C and fragmented by sonication as previously reported (25, 33), yielding fragments of average size approximately 350 bp. Antibodies against a C-terminal epitope of hER $\alpha$  (HC20) and against TBP were purchased from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany), and the antibody against phosphorylated polymerase II was purchased from Upstate Biotechnology, Inc. (Buckingham, UK). The sequences of the primers used in ChIP assays (synthesized by MWG GmbH, Ebersberg, Germany) are available upon request.

### Acknowledgments

We thank Thomas Bédouin for assistance with initial screening for EREs; Robert Sladek, Amy Hauth, and Franz Lang for helpful discussions; and Marie Pageau (Biochemistry, University of Montréal) for help with access to computers.

Received November 13, 2003. Accepted February 26, 2004.

Address all correspondence and requests for reprints to: Sylvie Mader, Département de Biochimie, Université de Montréal, CP 6128 Succursale Centre-Ville, Montréal, Québec, Canada H3C 3J7. E-mail: sylvie.mader@umontreal.ca.

This work was supported by Canadian Institutes of Health Research (CIHR) and Natural Sciences and Engineering Research Council (NSERC) grants (to S.M.); funding from the Fonds de la Recherche en Santé du Québec (FRSQ) and from Genome Canada and Genome Quebec for the Steroid Atlas project (to S.M. and J.H.W.); and by European Molecular Biology Organization (EMBO) and European Molecular Biology Laboratory (EMBL) grants (to F.G.). V.B. acknowledges support from a CIHR Strategic Program to the Montreal Center for Experimental Therapeutics in Cancer and from a CIHR postdoctoral fellowship. J.D. is recipient of a studentship from the FRSQ, and R.M. was supported by a long-term fellowship from EMBO. J.H.W. and S.M. are chercheurs-boursiers of FRSQ, and S.M. holds the Canadian Imperial Bank of Commerce Breast Cancer Research Chair at Université de Montréal.

Present address for R.M.: Equipe EMR; Unité Mixte de Recherche 6026, Centre National de la Recherche Scientifique, Campus de Beaulieu, 35046 Rennes Cedex, France.

### Note Added in Proof

A database of estrogen-responsive genes was published while this article was in revision (ERGDB, Ref. 134). This database, compiled from a literature review of experimentally identified estrogen target genes, includes putative ERE sequences found in some of these genes through screening of their promoter-proximal sequences with Dragon ERE Finder version 2.0. Our database includes all ERGDB EREs that correspond to sequences used in our screen (although positions may vary, as our study used a later release of the human and mouse genomes), but also ERE sequences found beyond the cutoff distance used for the ERGDB ( $-4500$  to  $+500$  bp from transcriptional start sites), or located in genes not currently known to respond to estrogen.

### REFERENCES

1. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? *Endocr Rev* 20:358–417

2. McEwen BS, Alves SE 1999 Estrogen actions in the central nervous system. *Endocr Rev* 20:279–307
3. Jordan VC 2001 Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. *J Natl Cancer Inst* 93:2–4
4. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. *Physiol Rev* 81:1535–1565
5. Green S, Chambon P 1988 Nuclear receptors enhance our understanding of transcription regulation. *Trends Genet* 4:309–314
6. Beato M, Herrlich P, Schütz G 1995 Steroid hormone receptors: many actors in search of a plot. *Cell* 83:851–857
7. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor family: the second decade. *Cell* 83:835–839
8. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ 2001 Nuclear receptors and lipid physiology: opening the X-files. *Science* 294:1866–1870
9. Robinson-Rechavi M, Escriva Garcia H, Laudet V 2003 The nuclear receptor superfamily. *J Cell Sci* 116:585–586
10. Krust A, Green S, Argos P, Kumar V, Walter P, Bornert JM, Chambon P 1986 The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. *EMBO J* 5:891–897
11. Mader S, Chambon P, White JH 1993 Defining a minimal estrogen receptor DNA binding domain. *Nucleic Acid Res* 21:1125–1132
12. Kumar V, Chambon P 1988 The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. *Cell* 55:145–156
13. Fawell SE, Lees JA, White R, Parker MG 1990 Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. *Cell* 60:953–962
14. Cowley SM, Hoare S, Mosselman S, Parker MG 1997 Estrogen receptors  $\alpha$  and  $\beta$  form heterodimers on DNA. *J Biol Chem* 272:19858–19862
15. Kato S, Tora L, Yamauchi J, Masushige S, Bellard M, Chambon P 1992 A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5'-TGACC-3' motifs acting synergistically. *Cell* 68:731–742
16. Vanacker J-M, Petterson K, Gustafsson J-A, Laudet V 1999 Transcriptional targets shared by estrogen receptor-related (ERRs) and estrogen receptor (ER) $\alpha$ , but not ER $\beta$ . *EMBO J* 18:4270–4279
17. Klinge CM 2001 Estrogen receptor interaction with estrogen response elements. *Nucleic Acids Res* 29:2905–2919
18. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU 1986 An estrogen-responsive element derived from the 5' flanking region of the *Xenopus vitellogenin A2* gene functions in transfected human cells. *Cell* 46:1053–1061
19. Sanchez R, Nguyen D, Rocha W, White JH, Mader S 2002 Diversity in the mechanisms of gene regulation by estrogen receptors. *Bioessays* 24:244–254
20. Glass CK 1994 Differential recognition of target genes by nuclear receptor monomers, dimers and heterodimers. *Endocr Rev* 15:391–407
21. Khorasanizadeh S, Rastinejad F 2001 Nuclear-receptor interactions on DNA-response elements. *Trends Biochem Sci* 26:384–390
22. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM 1999 Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. *Cell* 98:675–686
23. Burakov D, Crofts LA, Chang CP, Freedman LP 2002 Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. *J Biol Chem* 277:14359–14362
24. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 103:843–852
25. Reid G, Hubner MR, Metivier R, Brand H, Kos M, Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ER $\alpha$  on responsive promoters is an integral feature of estrogen signaling. *Mol Cell* 11:695–707
26. Leo C, Chen JD 2000 The SRC family of nuclear receptor coactivators. *Gene* 245:1–11
27. Robyr D, Wolffe A, Wahli W 2000 Nuclear hormone receptor coregulators in action: diversity for shared tasks. *Mol Endocrinol* 14:329–346
28. Rosenfeld MG, Glass CK 2001 Coregulator codes of transcriptional regulation by nuclear receptors. *J Biol Chem* 276:36865–36868
29. Rachez C, Freedman LP 2001 Mediator complexes and transcription. *Curr Opin Cell Biol* 13:274–280
30. Dilworth FJ, Chambon P 2001 Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. *Oncogene* 20:3047–3054
31. McDonnell DP, Norris JD 2002 Connections and regulation of the human estrogen receptor. *Science* 296:1642–1644
32. Belandia B, Parker MG 2003 Nuclear receptors: a rendezvous for chromatin remodeling factors. *Cell* 114:277–280
33. Métivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F 2003 Estrogen receptor- $\alpha$  directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. *Cell* 115:751–763
34. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P 2000 Estrogen receptor pathways and AP-1. *J Steroid Biochem Mol Biol* 74:311–317
35. Safe S 2001 Transcriptional activation of genes by 17 $\beta$ -estradiol through estrogen receptor-Sp1 interactions. *Vitam Horm* 62:231–252
36. Kelly MJ, Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. *Trends Endocrinol Metab* 12:152–156
37. McEwen B, Akama K, Alves S, Brake WG, Bulloch K, Lee S, Li C, Yuen G, Milner TA 2001 Tracking the estrogen receptor in neurons: implications for estrogen-induced synapse formation. *Proc Natl Acad Sci USA* 98:7093–7100
38. Moggs JG, Orphanides G 2001 Estrogen receptors: orchestrators of pleiotropic cellular responses. *EMBO Rep* 2:775–781
39. Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T, Ikegami A, Ouchi Y, Orimo H, Muramatsu M 1993 Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. *Proc Natl Acad Sci USA* 90:11117–11121
40. Watanabe T, Inoue S, Hiroi H, Orimo A, Kawashima H, Muramatsu M 1998 Isolation of estrogen-responsive genes with a CpG island library. *Mol Cell Biol* 18:442–449
41. Ikeda K, Sato M, Tsutsumi O, Tsuchiya F, Tsuneizumi M, Emi M, Imoto I, Inazawa J, Muramatsu M, Inoue S 2000 Promoter analysis and chromosomal mapping of human EBAG9 gene. *Biochem Biophys Res Commun* 273:654–660
42. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin JC, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kanne L, Lehoczky J, LeVine R, McEwan P, Mckernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor

- J, *et al* 2001 Initial sequencing and analysis of the human genome. *Nature* 409:860–921
43. Tsai S-J, Wu M-H, Chen H-M, Chuang P-C, Wing L-YC 2002 Fibroblast growth factor-9 is an endometrial stromal growth factor. *Endocrinology* 143:2715–2721
  44. Cohen RI, Chandross KJ 2000 Fibroblast growth factor-9 modulates the expression of myelin related proteins and multiple fibroblast growth factor receptors in developing oligodendrocytes. *J Neurosci Res* 61: 273–287
  45. Colvin JS, Green RP, Schmahl J, Capel B, Ornitz DM 2001 Male-to-female sex reversal in mice lacking fibroblast growth factor 9. *Cell* 104:875–889
  46. Toshima J, Ohashi K, Okano I, Nunoue K, Kishioka M, Kuma K, Miyata T, Hirai M, Baba T, Mizuno K 1995 Identification and characterization of a novel protein kinase, TESK1, specifically expressed in testicular germ cells. *J Biol Chem* 270:31331–31337
  47. Toshima J, Koji T, Mizuno K 1998 Stage-specific expression of testis-specific protein kinase 1 (TESK1) in rat spermatogenic cells. *Biochem Biophys Res Commun* 249:107–112
  48. Venables JP, Vernet C, Chew SL, Elliott DJ, Cowmeadow RB, Wu J, Cooke HJ, Artzt K, Eperon IC 1999 T-STAR/ETOILE: a novel relative of SAM68 that interacts with an RNA-binding protein implicated in spermatogenesis. *Hum Mol Genet* 8:959–969
  49. Valve E, Penttila TL, Paranko J, Harkonen P 1997 FGF-8 is expressed during specific phases of rodent oocyte and spermatogonium development. *Biochem Biophys Res Commun* 232:173–177
  50. Kang HY, Yeh S, Fujimoto N, Chang C 1999 Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. *J Biol Chem* 274:8570–8576
  51. Couse JE, Mahato D, Eddy EM, Korach KS 2001 Molecular mechanism of estrogen action in the male: insights from the estrogen receptor null mice. *Reprod Fertil Dev* 13:211–219
  52. Murata Y, Robertson KM, Jones ME, Simpson ER 2002 Effect of estrogen deficiency in the male: the ArKO mouse model. *Mol Cell Endocrinol* 193:7–12
  53. Carreau S 2003 Estrogens—male hormones? *Folia Histochem Cytobiol* 41:107–111
  54. Soulez M, Parker MG 2001 Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. *J Mol Endocrinol* 27:259–274
  55. Mally MI, Cirulli V, Otonkoski T, Soto G, Hayek A 1996 Ontogeny and tissue distribution of human GAD expression. *Diabetes* 45:496–501
  56. McCarthy MM, Kaufman LC, Brooks PJ, Pfaff DW, Schwartz-Giblin S 1995 Estrogen modulation of mRNA levels for the two forms of glutamic acid decarboxylase (GAD) in female rat brain. *J Comp Neurol* 360:685–697
  57. Bosma PT, Blazquez M, Fraser EJ, Schulz RW, Docherty K, Trudeau VL 2001 Sex steroid regulation of glutamate decarboxylase mRNA expression in goldfish brain is sexually dimorphic. *J Neurochem* 76:945–956
  58. Wondisford FE, Radovick S, Moates JM, Usala SJ, Weintraub BD 1988 Isolation and characterization of the human thyrotropin  $\beta$ -subunit gene. Differences in gene structure and promoter function from murine species. *J Biol Chem* 263:12538–12542
  59. Gurr JA, Vrontakis ME, Athanasian EA, Wagner CR, Kourides IA 1986 Hormonal regulation of thyrotropin  $\alpha$  and  $\beta$  subunit mRNAs. *Horm Metab Res* 18:382–385
  60. Podvinec M, Kaufmann MR, Handschin C, Meyer UA 2002 NUBIScan, an in silico approach for prediction of nuclear receptor response elements. *Mol Endocrinol* 16:1269–1279
  61. Bajic VB, Tan SL, Chong A, Tang S, Strom A, Gustafsson JA, Lin CY, Liu ET 2003 Dragon ERE Finder version 2: a tool for accurate detection and analysis of estrogen response elements in vertebrate genomes. *Nucleic Acids Res* 31:3605–3607
  62. Iyer VR, Horak CE, Scafe CS, Botstein D, Snyder M, Brown PO 2001 Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. *Nature* 409:533–538
  63. Lieb JD, Liu X, Botstein D, Brown PO 2001 Promoter-specific binding of Rap1 revealed by genome-wide maps of protein-DNA association. *Nat Genet* 28: 327–334
  64. Topalidou I, Thireos G 2003 Gcn4 occupancy of open reading frame regions results in the recruitment of chromatin-modifying complexes but not the mediator complex. *EMBO Rep* 4:872–876
  65. Martone R, Euskirchen G, Bertone P, Hartman S, Royce TE, Luscombe NM, Rinn JL, Nelson FK, Miller P, Gerstein M, Weissman S, Snyder M 2003 Distribution of NF- $\kappa$ B-binding sites across human chromosome 22. *Proc Natl Acad Sci USA* 100:12247–12252
  66. Toft D, Gorski J 1966 A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. *Proc Natl Acad Sci USA* 55: 1574–1581
  67. Clark JH, Gorski J 1970 Ontogeny of the estrogen receptor during early uterine development. *Science* 169: 76–78
  68. Notides AC 1970 The binding affinity and specificity of the estrogen receptor of the rat uterus and anterior pituitary. *Endocrinology* 87:987–992
  69. Stumpf WE, Sar M, Zuber TJ, Soini E, Tuohimaa P 1981 Quantitative assessment of steroid hormone binding sites by thaw-mount autoradiography. *J Histochem Cytochem* 29:201–206
  70. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B 2003 Genomic targets of the human c-Myc protein. *Genes Dev* 17:1115–1129
  71. Bhat RA, Harnish DC, Stevis PE, Lyttle CR, Komm BS 1998 A novel human estrogen receptor  $\beta$ : identification and functional analysis of additional N-terminal amino acids. *J Steroid Biochem Mol Biol* 67:233–240
  72. Green S, Issemann I, Sheer E 1988 A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. *Nucleic Acids Res* 16:369
  73. Nguyen D, Steinberg SV, Rouault E, Chagnon S, Gottlieb B, Pinsky L, Trifiro M, Mader S 2001 A G577R mutation in the human AR P box results in selective decreases in DNA binding and in partial androgen insensitivity syndrome. *Mol Endocrinol* 15:1790–1802
  74. Agarwal A, Yeung WS, Lee KF 2002 Cloning and characterization of the human oviduct-specific glycoprotein (HuOGP) gene promoter. *Mol Hum Reprod* 8:167–175
  75. Takahashi K, Sendai Y, Matsuda Y, Hoshi H, Hiroi M, Araki Y 2000 Mouse oviduct-specific glycoprotein gene: genomic organization and structure of the 5'-flanking regulatory region. *Biol Reprod* 62:217–226
  76. Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A 1999 Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. *Hypertension* 33: 108–115
  77. Congiu M, Clouston WM, Fernley RT, Richards RI 1992 The function of conserved elements in the promoter of the mouse angiotensinogen gene. *J Mol Endocrinol* 9:19–29
  78. Berry M, Nunez A-M, Chambon P 1989 Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. *Proc Natl Acad Sci USA* 86:1218–1222
  79. Richard S, Zingg HH 1990 The human oxytocin promoter is regulated by estrogens. *J Biol Chem* 265: 6098–6103
  80. Perillo B, Sasso A, Abbondanza C, Palumbo G 2000 17 $\beta$ -Estradiol inhibits apoptosis in MCF-7 cells, induc-

- ing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. *Mol Cell Biol* 20:2890–2901
81. Citarella F, Misiti S, Felici A, Aiuti A, La Porta C, Fantoni A 1993 The 5' sequence of human Factor XII gene contains transcription regulatory elements typical of liver specific, estrogen-modulated genes. *Biochim Biophys Acta* 1172:197–199
  82. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, Orimo A, Inoue M 1999 Estrogen activates telomerase. *Cancer Res* 59:5917–5921
  83. Fan JD, Wagner BL, McDonnell DP 1996 Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. *Mol Endocrinol* 10:1605–1616
  84. Augereau P, Miralles F, Cavallès V, Gaudalet C, Parker M, Rochefort H 1994 Characterization of the proximal estrogen-responsive element of human cathepsin D gene. *Mol Endocrinol* 8:693–703
  85. Teng CT, Liu Y, Yang N, Walmer D, Panella T 1992 Differential molecular mechanism of the estrogen action that regulates lactoferrin gene in human and mouse. *Mol Endocrinol* 6:1969–1981
  86. Lee M, Liu Y, Zhang X 1995 A retinoic acid response element that overlaps an estrogen response element mediates multihormonal sensitivity in transcriptional activation of the lactoferrin gene. *Mol Cell Biol* 15:4194–4207
  87. Lobenhofer EK, Bennett L, Cable PL, Li L, Bushel PR, Afshari CA 2002 Regulation of DNA replication fork genes by 17 $\beta$ -estradiol. *Mol Endocrinol* 16:1215–1229
  88. Revillion F, Pawlowski V, Hornez L, Peyrat JP 2000 Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. *Eur J Cancer* 36:1038–1042
  89. Ghosh MG, Thompson DA, Weigel RJ 2000 PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. *Cancer Res* 60:6367–6375
  90. Hashimoto S, Miwa M, Akasofu K, Nishida E 1991 Changes in 40 serum proteins of post-menopausal women. *Maturitas* 13:23–33
  91. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S 2002 Development of cDNA microarray for expression profiling of estrogen-responsive genes. *J Mol Endocrinol* 29:175–192
  92. Bhat KP, Pezzuto JM 2001 Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. *Cancer Res* 61:6137–6144
  93. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA 2002 Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. *Biol Reprod* 66:297–304
  94. Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER 2002 Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. *J Biol Chem* 277:50768–50775
  95. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laffin KJ, Gaddis S, MacLeod MC, Aldaz CM 2000 Effects of estrogen on global gene expression: identification of novel targets of estrogen action. *Cancer Res* 60:5977–5983
  96. Xie T, Ho SL, Ramsden D 1999 Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. *Mol Pharmacol* 56:31–38
  97. Seth P, Krop I, Porter D, Polyak K 2002 Novel estrogen and tamoxifen induced genes identified by SAGE (serial analysis of gene expression). *Oncogene* 21:836–843
  98. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, Klein-Szanto AJ 2000 E2F-1: a proliferative marker of breast neoplasia. *Cancer Epidemiol Biomarkers Prev* 9:395–401
  99. Seo HS, Larsimont D, Querton G, El Khissiini A, Laios N, Legros N, Leclercq G 1998 Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. *Int J Cancer* 78:760–765
  100. Shimomura Y, Matsuo H, Samoto T, Maruo T 1998 Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. *J Clin Endocrinol Metab* 83:2192–2198
  101. Kuang WW, Thompson DA, Hoch RV, Weigel RJ 1998 Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. *Nucleic Acids Res* 26:1116–1123
  102. Piotrowicz RS, Ding L, Maher P, Levin EG 2001 Inhibition of cell migration by 24-kDa fibroblast growth factor-2 is dependent upon the estrogen receptor. *J Biol Chem* 276:3963–3970
  103. Kumar P, Mark PJ, Ward BK, Minchin RF, Ratajczak T 2001 Estradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells. *Biochem Biophys Res Commun* 284:219–225
  104. Duan R, Porter W, Safe S, Weisz A, Rosales R 1998 Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. *Endocrinology* 139:1981–1990
  105. Daly RJ, Gu H, Parmar J, Malaney S, Lyons RJ, Kairouz R, Head DR, Henshall SM, Neel BG, Sutherland RL 2002 The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. *Oncogene* 21:5175–5181
  106. Ormandy CJ, Lee CS, Ormandy HF, Fantl V, Shine J, Peters G, Sutherland RL 1998 Amplification, expression, and steroid regulation of the preprogalanin gene in human breast cancer. *Cancer Res* 58:1353–1357
  107. Kang SK, Choi KC, Tai CJ, Auersperg N, Leung PC 2001 Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. *Endocrinology* 142:580–588
  108. Inadera H, Hashimoto S, Dong HY, Suzuki T, Nagai S, Yamashita T, Toyoda N, Matsushima K 2000 WISP-2 as a novel estrogen-responsive gene in human breast cancer cells. *Biochem Biophys Res Commun* 275:108–114
  109. Tschugguel W, Stonek F, Zhegu Z, Dietrich W, Schneeberger C, Stimpfl T, Waldhoer T, Vucudilik W, Huber JC 2001 Estrogen increases endothelial carbon monoxide, heme oxygenase 2, and carbon monoxide-derived cGMP by a receptor-mediated system. *J Clin Endocrinol Metab* 86:3833–3839
  110. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D 1999 Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression *in vitro* and *in vivo*. *Mol Endocrinol* 13:787–796
  111. Molloy CA, May FE, Westley BR 2000 Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. *J Biol Chem* 275:12565–12571
  112. Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, Surmacz E, Ando S 2001 Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. *Biochem Biophys Res Commun* 288:685–689

113. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV 2001 Re-expression of estrogen receptor  $\alpha$  in estrogen receptor  $\alpha$ -negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. *Cancer Res* 61:5771–5777
114. Pentecost BT 1998 Expression and estrogen regulation of the HEM45 mRNA in human tumor lines and in the rat uterus. *J Steroid Biochem Mol Biol* 64:25–33
115. Choi I, Gudas LJ, Katzenellenbogen BS 2000 Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. *Mol Cell Endocrinol* 164:225–237
116. Seth P, Porter D, Lahti-Domenici J, Geng Y, Richardson A, Polyak K 2002 Cellular and molecular targets of estrogen in normal human breast tissue. *Cancer Res* 62:4540–4544
117. Moalli PA, Klingensmith WL, Meyn LA, Zyczynski HM 2002 Regulation of matrix metalloproteinase expression by estrogen in fibroblasts that are derived from the pelvic floor. *Am J Obstet Gynecol* 187:72–79
118. Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhn P, Stahl RA 2003 Linked common polymorphisms in the gelatinase promoter are associated with diminished transcriptional response to estrogen and genetic fitness. *J Biol Chem* 278:20490–20499
119. Marin-Castano ME, Elliot SJ, Potier M, Karl M, Striker LJ, Striker GE, Csaky KG, Cousins SW 2003 Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. *Invest Ophthalmol Vis Sci* 44:50–59
120. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U 1998 Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. *Hypertension* 31:582–588
121. Skaar TC, Prasad SC, Sharareh S, Lippman ME, Brunner N, Clarke R 1998 Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. *J Steroid Biochem Mol Biol* 67:391–402
122. Prange-Kiel J, Rune GM, Zwirner M, Wallwiener D, Kiesel L 2001 Regulation of estrogen receptor  $\alpha$  and progesterone receptor (isoform A and B) expression in cultured human endometrial cells. *Exp Clin Endocrinol Diabetes* 109:231–237
123. Martini PG, Katzenellenbogen BS 2001 Regulation of prothymosin  $\alpha$  gene expression by estrogen in estrogen receptor-containing breast cancer cells via upstream half-palindromic estrogen response element motifs. *Endocrinology* 142:3493–3501
124. Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, Kanaya T, Nakamura M, Koike K, Hisamoto K, Ohmichi M, Inoue M 2002 Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. *Oncogene* 21:3517–3524
125. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS 2001 Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. *Cancer Res* 61:5979–5984
126. Qin C, Nguyen T, Stewart J, Samudio I, Burghardt R, Safe S 2002 Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor  $\kappa$ B/CCAAT-binding transcription factor-1 complex. *Mol Endocrinol* 16:1793–1809
127. Duque G, Abdaimi KE, Macoritto M, Miller MM, Kremer R 2002 Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation. *Biochem Biophys Res Commun* 299:446–454
128. Katoh M 2003 Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by  $\beta$ -estradiol in MCF-7 cells. *Int J Oncol* 22:209–212
129. Kirikoshi H, Katoh M 2002 Expression and regulation of WNT10B in human cancer: up-regulation of WNT10B in MCF-7 cells by  $\beta$ -estradiol and down-regulation of WNT10B in NT2 cells by retinoic acid. *Int J Mol Med* 10:507–511
130. Kirikoshi H, Sekihara H, Katoh M 2001 Expression of WNT14 and WNT14B mRNAs in human cancer, up-regulation of WNT14 by IFN $\gamma$  and up-regulation of WNT14B by  $\beta$ -estradiol. *Int J Oncol* 19:1221–1225
131. Levenson AS, Svoboda KM, Pease KM, Kaiser SA, Chen B, Simons LA, Jovanovic BD, Dyck PA, Jordan VC 2002 Gene expression profiles with activation of the estrogen receptor  $\alpha$ -selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. *Cancer Res* 62:4419–4426
132. Frasar J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. *Endocrinology* 144:4562–4574
133. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC 2003 Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ER $\alpha$  or ER $\beta$ . *J Cell Biochem* 90:315–326
134. Tang S, Han H, Bajic VB 2004 ERGDB: estrogen responsive genes database. *Nucleic Acids Res* 32:D533–D536

